SCHEMBL2459006

SCHEMBL2459006

O=C(O)c1ccc(=O)n(-c2ccc(F)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
LMNA P02545 2/20 0.51
BCL2L1 Q07817 1/20 0.48
BAD Q92934 1/20 0.48
HTR7 P34969 1/20 0.43
MITF O75030 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
DDAH1 O94760 1/20 0.41
KMT2A Q03164 2/20 0.40
MEN1 O00255 1/20 0.40
PDK1 Q15118 1/20 0.40
PDK2 Q15119 1/20 0.40
MAPT P10636 2/20 0.40
DUSP22 Q9NRW4 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474401 0.85 HSD17B10 (0.43) KDM4ELMNACES2CES1KMT2A
SCHEMBL24849954 0.85 BCL2L1 (0.39) KDM4ELMNABCL2L1BADHTR7
SCHEMBL146048 0.84 KDM4E (0.56) KDM4ELMNACES2CES1DDAH1
SCHEMBL16672361 0.83 SRD5A2 (0.54) CES2CES1KMT2AMEN1HPGD
SCHEMBL4246208 0.83 ALDH1A1 (0.56) KDM4ELMNACES2CES1DDAH1
SCHEMBL11896214 0.83 ALOX15 (0.53) KDM4ECES2CES1DDAH1KMT2A
SCHEMBL16672330 0.81 L3MBTL1 (0.53) KDM4ECES2CES1KMT2AMEN1
SCHEMBL2459873 0.81 KMT2A (0.52) KDM4ELMNAKMT2AMEN1MAPT
SCHEMBL12311154 0.79 CA1 (0.58) KDM4ECES2CES1KMT2AMEN1
SCHEMBL11896441 0.79 NPC1 (0.49) KDM4EKMT2AMEN1MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002346-A1 NEW COMPOUNDS AND METHODS BenevolentAl Bio Limited (GB) 2023-01-05 US disclosed
US-20230002346-A1 NEW COMPOUNDS AND METHODS BenevolentAl Bio Limited (GB) 2023-01-05 US disclosed
EP-3060549-B1 NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE DAE WOONG PHARMA (KR) 2019-02-13 EP disclosed
CN-105745193-B Antimycotic oxo-dihydro pyridine carbohydrazide derivative 株式会社大熊制药 2017-12-01 CN disclosed
US-9617216-B2 Antifungal oxodihydropyridinecarbohydrazide derivative DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-04-11 US disclosed
US-20160304460-A1 NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-10-20 US disclosed
EP-3060549-A1 NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE Daewoong Pharmaceutical Co., Ltd. (KR) 2016-08-31 EP disclosed
CN-105745193-A Novel antifungal oxodihydropyridinecarbohydrazide derivative 株式会社大熊制药 2016-07-06 CN disclosed
WO-2015060613-A1 NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-30 WO disclosed
US-8791147-B2 Calcium receptor modulating agents AMGEN INC. (US) 2014-07-29 US disclosed
US-8791147-B2 Calcium receptor modulating agents AMGEN INC. (US) 2014-07-29 US disclosed
US-8791147-B2 Calcium receptor modulating agents AMGEN INC. (US) 2014-07-29 US disclosed
US-20110230517-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-09-22 US disclosed
US-20110230517-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-09-22 US disclosed
US-20110230517-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. 2011-09-22 US disclosed
WO-2010042642-A1 CALCIUM RECEPTOR MODULATING AGENTS AMGEN INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002346-A1 NEW COMPOUNDS AND METHODS ABL2, ABL1, ALK KDM4E 3546/4885LMNA 1857/4885BCL2L1 1373/4885
US-20160304460-A1 NOVEL ANTIFUNGAL OXODIHYDROPYRIDINECARBOHYDRAZIDE DERIVATIVE PITHD1, HPD, QDPR KDM4E 841/4885LMNA 4833/4885BCL2L1 2059/4885
US-20110230517-A1 CALCIUM RECEPTOR MODULATING AGENTS CASR, CALCR, CNR1 KDM4E 4037/4885LMNA 3106/4885BCL2L1 1079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.